Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Mazen S. Bader"'
Autor:
Annie Brooks, Abdulmajeed Alosali, Mazen S. Bader, Neal Irfan, Dominik Mertz, Daniela Leto, Ali Someili, Amir Hadzic
Publikováno v:
Infectious Diseases in Clinical Practice. 29:e361-e365
Autor:
Mazen S. Bader, Dominik Mertz, John Hawboldt, Alison Farrell, Abdulaziz Alajmi, Keon Maleki-Yazdi
Publikováno v:
Infectious Diseases in Clinical Practice. 30
Autor:
Annie Brooks, Neal Irfan, Dominik Mertz, Mazen S. Bader, Yasmeen Marbaniang Vincent, Alison Farrell, John Hawboldt
Publikováno v:
Infectious Diseases. 53:255-273
Diabetic foot is one of the common complications of diabetes mellitus. We report clinical and microbiological characteristics and outcomes of cases with distant metastatic foci of infection arising from diabetic foot.Retrospective review of adult pat
Autor:
Alison Farrell, John Hawboldt, Mazen S. Bader, Joanna Joyce, Mark Loeb, Cheryl Main, Dominik Mertz
Publikováno v:
Infectious Diseases. 52:847-857
Guidelines recommend oral vancomycin as first-line therapy for Clostridioides difficile infection. Guideline recommendations vary regarding dosing of vancomycin. Our aim was to summarize the curren...
Publikováno v:
Infectious Diseases in Clinical Practice. 29:e468-e470
Given COVID-19 rise in populations with high burden of tuberculosis infection, the interplay between COVID-19 and tuberculosis reactivation needs further investigation. We report a case of a 64-year-old man who developed acute respiratory distress sy
Publikováno v:
Infectious Diseases in Clinical Practice. 28:22-26
Autor:
Mazen S, Bader, John, Hawboldt, Cheryl, Main, Dominik, Mertz, Mark, Loeb, Alison, Farrell, Joanna, Joyce
Publikováno v:
Infectious diseases (London, England). 52(12)
Guidelines recommend oral vancomycin as first-line therapy forWe searched clinical studies and major guidelines in the English language using MEDLINE, the Cochrane Library and Embase from 1985 until 15 April 2020.No evidence supports the use of high
Autor:
Annie Brooks, A Alosail, Neal Irfan, A Hadzic, A Someili, Daniela Leto, A Alajmi, Mazen S. Bader, Dominik Mertz
Background Vancomycin is the recommended first-line therapy for mild to severe Clostridioides difficile infection (CDI). However, oral vancomycin is associated with disruption of the indigenous microbiota, predisposing patients to overgrowth of endog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec910b86c0729e2962de200aa834d745
https://europepmc.org/articles/PMC7043652/
https://europepmc.org/articles/PMC7043652/
Publikováno v:
Infectious Diseases in Clinical Practice. 25:29-32
Autor:
Mazen S. Bader, Vaibhav Mokashi
Publikováno v:
The Lancet Infectious Diseases. 20:1216